Full text is available at the source.
Abstract
Interindividual variability in weight-loss response to glucagon-like peptide-1 receptor agonists (GLP-1RAs) is significant.
- The determinants of varied weight-loss responses to GLP-1RAs are not fully understood.
- An integrated framework is proposed to better understand the mechanisms behind this variability.
- Biologically defined obesity phenotypes may play a role in informing precision treatment strategies.
Simplified